
Opinion|Videos|May 12, 2025
The Evolvement of Imaging in ccRCC
Panelists discuss how cross-sectional imaging with pre- and postcontrast assessment remains the cornerstone of renal mass imaging, though newer software technologies now allow for better prediction of benign vs malignant tumors.
Advertisement
Episodes in this series

Now Playing
Evolution of Imaging in Renal Cell Carcinoma (RCC)
Main Discussion Topics:
- Cross-sectional imaging with pre- and postcontrast assessment remains the cornerstone of renal mass evaluation.
- Advanced software developments now allow for better assessment of images, potentially helping predict benign vs malignant masses.
- Ongoing efforts to develop a “clear cell RCC score” based on MRI parameters to identify clear cell carcinoma vs benign tumors
Key Points for Physicians:
- Cross-sectional imaging with contrast remains essential for initial evaluation.
- New software assessment tools may improve diagnostic accuracy.
- Specialized MRI parameters show promise for distinguishing clear cell RCC from other masses.
Notable Insights:
The panel emphasized that although advanced imaging techniques are emerging, the fundamental approach of cross-sectional imaging with contrast has remained consistent for decades.
Clinical Significance:
New image processing technologies are enhancing traditional imaging modalities, potentially allowing for better risk stratification without increasing invasiveness.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
FDA updates in urology: May 2026
5











